software getdata graph digitizer version 2.26 (GetData Pty Ltd)
90
Structured Review
GetData Pty Ltd
software getdata graph digitizer version 2.26
Software Getdata Graph Digitizer Version 2.26, supplied by GetData Pty Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/graph+digitizer+software+getdata+digitizer+version+2%2E26/graph+digitizer/pm37890524-84-3-4
Average 90 stars, based on 1 article reviews
Software Getdata Graph Digitizer Version 2.26, supplied by GetData Pty Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/graph+digitizer+software+getdata+digitizer+version+2%2E26/graph+digitizer/pm37890524-84-3-4
Average 90 stars, based on 1 article reviews
software getdata graph digitizer version 2.26 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Derivative Assay:Article Title: Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy. Article Snippet: This study compared the quality-adjusted effectiveness and costs of three treatment options for transplant-eligible patients with early progression (POD24) of follicular lymphoma.. A Markov decision-analytic model using a 20-year time horizon was used to compare allogeneic stem cell transplant (alloSCT), autologous stem cell transplant (ASCT), and chemo-immunotherapy (O-CHOP).. For second relapse/refractory disease, novel therapy use was modeled, including lenalidomide and rituximab/obinutuzumab, and PI3K inhibitors (PI3Ki). Software:Article Title: Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy. Article Snippet: This study compared the quality-adjusted effectiveness and costs of three treatment options for transplant-eligible patients with early progression (POD24) of follicular lymphoma.. A Markov decision-analytic model using a 20-year time horizon was used to compare allogeneic stem cell transplant (alloSCT), autologous stem cell transplant (ASCT), and chemo-immunotherapy (O-CHOP).. For second relapse/refractory disease, novel therapy use was modeled, including lenalidomide and rituximab/obinutuzumab, and PI3K inhibitors (PI3Ki). |